Stockreport

Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption

PLUS THERAPEUTICS, Inc.  (PSTV) 
PDF HOUSTON, April 07, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing preci [Read more]